Towards equitable and sustainable availability of blood products in Zimbabwe: An analysis of strengths, weaknesses, opportunities and challenges

Blood transfusion can be a lifesaving intervention in a number of medical emergencies. To attain sustainable and equitable availability of blood products, it is important to understand the strengths, weaknesses, opportunities, and challenges of the national blood services programme. We, therefore, w...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion clinique et biologique : journal de la Société française de transfusion sanguine 2022-08, Vol.29 (3), p.273-275
Main Authors: Denhere, K., Dzinamarira, T., Tungwarara, N., Kampira, V., Chitungo, I., Mataruka, K., Mukwenha, S., Musuka, G., Murewanhema, G.
Format: Article
Language:English
Subjects:
Blood
Blood products
Blood transfusion
Healthcare
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Blood transfusion can be a lifesaving intervention in a number of medical emergencies. To attain sustainable and equitable availability of blood products, it is important to understand the strengths, weaknesses, opportunities, and challenges of the national blood services programme. We, therefore, with this letter to the editor, discuss some of the strengths, weaknesses, opportunities and threats to the Zimbabwean programme since its inception. Despite several strengths and opportunities that the national blood services of Zimbabwe (NBSZ) leverages on, we argue that among other challenges, donor shortages and an upsurge of transfusion transmittable infections in the eligible donor population continue to be the biggest threats to the achievement of the programme objectives. These can be addressed through expanding the blood donor base and the catchment area. Additionally, improving the level of knowledge and attitude towards blood donation in the communities is critical for driving the sustainable and equitable distribution of safe blood products to the population.
ISSN:1246-7820
DOI:10.1016/j.tracli.2022.06.006